LinqMed Inc., a certified venture company of the National Institutes for Quantum Sciences and Technology (QST), is a start-up radiopharmaceutical company to provide innovative “visible” anti-cancer treatments to patients.

Cancer is one of the leading cause of death in the world, and the development of diagnostic and therapeutic methods is an urgent task. We have so far developed next-generation radiopharmaceuticals that can be used for both the diagnosis and therapy of cancer, using the radioisotope of copper-64. Based on ⁶⁴Cu, we will continuously create various radiopharmaceuticals and contribute to technological innovation.

Through the manufacture and sale of radiopharmaceuticals, LinqMed Inc. links cutting-edge science and medicine for your health and happiness.

CEO / Yukie Yoshii